Literature DB >> 28446600

Management of suspected monogenic lung fibrosis in a specialised centre.

Raphael Borie1,2,3,4, Caroline Kannengiesser4,5, Flore Sicre de Fontbrune6, Laurent Gouya4,7,8,9, Nadia Nathan10,11, Bruno Crestani12,2,3,4.   

Abstract

At least 10% of patients with interstitial lung disease present monogenic lung fibrosis suspected on familial aggregation of pulmonary fibrosis, specific syndromes or early age of diagnosis. Approximately 25% of families have an identified mutation in genes mostly involved in telomere homeostasis, and more rarely in surfactant homeostasis.Beyond pathophysiological knowledge, detection of these mutations has practical consequence for patients. For instance, mutations involved in telomere homeostasis are associated with haematological complications after lung transplantation and may require adapted immunosuppression. Moreover, relatives may benefit from a clinical and genetic evaluation that should be specifically managed.The field of genetics of pulmonary fibrosis has made great progress in the last 10 years, raising specific problems that should be addressed by a specialised team.
Copyright ©ERS 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28446600     DOI: 10.1183/16000617.0122-2016

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  8 in total

1.  Familial pulmonary fibrosis: a world without frontiers.

Authors:  Raphael Borie; Bruno Crestani
Journal:  J Bras Pneumol       Date:  2019-10-07       Impact factor: 2.624

2.  The Role of Genetic Testing in Pulmonary Fibrosis: A Perspective From the Pulmonary Fibrosis Foundation Genetic Testing Work Group.

Authors:  Chad A Newton; Justin M Oldham; Carolyn Applegate; Nikkola Carmichael; Karen Powell; Dan Dilling; Shelley L Schmidt; Mary Beth Scholand; Mary Armanios; Christine Kim Garcia; Jonathan A Kropski; Janet Talbert
Journal:  Chest       Date:  2022-03-23       Impact factor: 10.262

3.  Monogenic gene variants in lung transplant recipients with usual interstitial pneumonia.

Authors:  Christoffer Stark; Juha W Koskenvuo; Antti Nykänen; Eija H Seppälä; Samuel Myllykangas; Karl Lemström; Peter Raivio
Journal:  ERJ Open Res       Date:  2022-01-24

4.  Use of antifibrotic drugs in familial interstitial pneumonia: analysis of one family.

Authors:  Deborah Dos Reis Estrella; Eliane Viana Mancuzo; Ricardo de Amorim Corrêa
Journal:  J Bras Pneumol       Date:  2021-12-15       Impact factor: 2.624

5.  Clustering of lung diseases in the family of interstitial lung disease patients.

Authors:  Michelle Terwiel; Jan C Grutters; Coline H M van Moorsel
Journal:  BMC Pulm Med       Date:  2022-04-07       Impact factor: 3.317

6.  Towards a global initiative for fibrosis treatment (GIFT).

Authors:  Maria Molina-Molina; Alvar Agusti; Bruno Crestani; David A Schwartz; Melanie Königshoff; Rachel C Chambers; Toby M Maher; Rosa Faner; Ana Lucia Mora; Mauricio Rojas; Katerina M Antoniou; Jacobo Sellares
Journal:  ERJ Open Res       Date:  2017-12-01

Review 7.  Discovering myeloid cell heterogeneity in the lung by means of next generation sequencing.

Authors:  Jing-Jing Ji; Jie Fan
Journal:  Mil Med Res       Date:  2019-10-25

8.  Clinical diagnosis of patients subjected to surgical lung biopsy with a probable usual interstitial pneumonia pattern on high-resolution computed tomography.

Authors:  Regina Celia Carlos Tibana; Maria Raquel Soares; Karin Mueller Storrer; Gustavo de Souza Portes Meirelles; Katia Hidemi Nishiyama; Israel Missrie; Ester Nei Aparecida Martins Coletta; Rimarcs Gomes Ferreira; Carlos Alberto de Castro Pereira
Journal:  BMC Pulm Med       Date:  2020-11-16       Impact factor: 3.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.